Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

112 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Safety and efficacy of ruxolitinib in myelofibrosis patients without splenomegaly.
Palandri F, Polverelli N, Breccia M, Nicolino B, Vitolo U, Alimena G, Cavo M, Vianelli N, Benevolo G. Palandri F, et al. Among authors: benevolo g. Br J Haematol. 2016 Jul;174(1):160-2. doi: 10.1111/bjh.13758. Epub 2015 Oct 28. Br J Haematol. 2016. PMID: 26507357 Free article. No abstract available.
Risk factors for infections in myelofibrosis: role of disease status and treatment. A multicenter study of 507 patients.
Polverelli N, Breccia M, Benevolo G, Martino B, Tieghi A, Latagliata R, Sabattini E, Riminucci M, Godio L, Catani L, Nicolosi M, Perricone M, Sollazzo D, Colafigli G, Campana A, Merli F, Vitolo U, Alimena G, Martinelli G, Lewis RE, Vianelli N, Cavo M, Palandri F. Polverelli N, et al. Among authors: benevolo g. Am J Hematol. 2017 Jan;92(1):37-41. doi: 10.1002/ajh.24572. Epub 2016 Nov 12. Am J Hematol. 2017. PMID: 27701770 Free article.
Driver mutations' effect in secondary myelofibrosis: an international multicenter study based on 781 patients.
Passamonti F, Mora B, Giorgino T, Guglielmelli P, Cazzola M, Maffioli M, Rambaldi A, Caramella M, Komrokji R, Gotlib J, Kiladjian JJ, Cervantes F, Devos T, Palandri F, De Stefano V, Ruggeri M, Silver R, Benevolo G, Albano F, Caramazza D, Rumi E, Merli M, Pietra D, Casalone R, Barbui T, Pieri L, Vannucchi AM. Passamonti F, et al. Among authors: benevolo g. Leukemia. 2017 Apr;31(4):970-973. doi: 10.1038/leu.2016.351. Epub 2016 Nov 25. Leukemia. 2017. PMID: 27885272 No abstract available.
Ruxolitinib for the treatment of inadequately controlled polycythaemia vera without splenomegaly (RESPONSE-2): a randomised, open-label, phase 3b study.
Passamonti F, Griesshammer M, Palandri F, Egyed M, Benevolo G, Devos T, Callum J, Vannucchi AM, Sivgin S, Bensasson C, Khan M, Mounedji N, Saydam G. Passamonti F, et al. Among authors: benevolo g. Lancet Oncol. 2017 Jan;18(1):88-99. doi: 10.1016/S1470-2045(16)30558-7. Epub 2016 Dec 2. Lancet Oncol. 2017. PMID: 27916398 Clinical Trial.
Efficacy and safety of ruxolitinib in intermediate-1 IPSS risk myelofibrosis patients: Results from an independent study.
Palandri F, Tiribelli M, Benevolo G, Tieghi A, Cavazzini F, Breccia M, Bergamaschi M, Sgherza N, Polverelli N, Crugnola M, Isidori A, Binotto G, Heidel FH, Buccisano F, Martino B, Latagliata R, Spinsanti M, Kallenberg L, Palumbo GA, Abruzzese E, Scaffidi L, Cuneo A, Cavo M, Vianelli N, Bonifacio M. Palandri F, et al. Among authors: benevolo g. Hematol Oncol. 2018 Feb;36(1):285-290. doi: 10.1002/hon.2429. Epub 2017 May 17. Hematol Oncol. 2018. PMID: 28512865
A clinical-molecular prognostic model to predict survival in patients with post polycythemia vera and post essential thrombocythemia myelofibrosis.
Passamonti F, Giorgino T, Mora B, Guglielmelli P, Rumi E, Maffioli M, Rambaldi A, Caramella M, Komrokji R, Gotlib J, Kiladjian JJ, Cervantes F, Devos T, Palandri F, De Stefano V, Ruggeri M, Silver RT, Benevolo G, Albano F, Caramazza D, Merli M, Pietra D, Casalone R, Rotunno G, Barbui T, Cazzola M, Vannucchi AM. Passamonti F, et al. Among authors: benevolo g. Leukemia. 2017 Dec;31(12):2726-2731. doi: 10.1038/leu.2017.169. Epub 2017 May 31. Leukemia. 2017. PMID: 28561069
Current options to manage Waldenström's macroglobulinemia.
Benevolo G, Nicolosi M, Santambrogio E, Vitolo U. Benevolo G, et al. Expert Rev Hematol. 2017 Jul;10(7):637-647. doi: 10.1080/17474086.2017.1339596. Epub 2017 Jun 19. Expert Rev Hematol. 2017. PMID: 28592170 Review.
Baseline factors associated with response to ruxolitinib: an independent study on 408 patients with myelofibrosis.
Palandri F, Palumbo GA, Bonifacio M, Tiribelli M, Benevolo G, Martino B, Abruzzese E, D'Adda M, Polverelli N, Bergamaschi M, Tieghi A, Cavazzini F, Ibatici A, Crugnola M, Bosi C, Latagliata R, Di Veroli A, Scaffidi L, de Marchi F, Cerqui E, Anaclerico B, De Matteis G, Spinsanti M, Sabattini E, Catani L, Aversa F, Di Raimondo F, Vitolo U, Lemoli RM, Fanin R, Merli F, Russo D, Cuneo A, Bacchi Reggiani ML, Cavo M, Vianelli N, Breccia M. Palandri F, et al. Among authors: benevolo g. Oncotarget. 2017 Jun 27;8(45):79073-79086. doi: 10.18632/oncotarget.18674. eCollection 2017 Oct 3. Oncotarget. 2017. PMID: 29108288 Free PMC article.
Life for patients with myelofibrosis: the physical, emotional and financial impact, collected using narrative medicine-Results from the Italian 'Back to Life' project.
Palandri F, Benevolo G, Iurlo A, Abruzzese E, Carella AM, Paoli C, Palumbo GA, Bonifacio M, Cilloni D, Andriani A, Guarini A, Turri D, Elli EM, Falcone A, Anaclerico B, Musto P, Di Renzo N, Tiribelli M, Zambello R, Spinosa C, Ricco A, Raucci L, Martino B, Annunziata M, Pascale S, Liberati AM, La Nasa G, Maffioli M, Breccia M, Pugliese N, Betti S, Giglio G, Cappuccio A, Reale L. Palandri F, et al. Among authors: benevolo g. Qual Life Res. 2018 Jun;27(6):1545-1554. doi: 10.1007/s11136-018-1827-2. Epub 2018 Mar 8. Qual Life Res. 2018. PMID: 29520559 Free article.
112 results